Literature DB >> 30466613

Periplocin, the most anti-proliferative constituent of Periploca sepium, specifically kills liposarcoma cells by death receptor mediated apoptosis.

Birgit Lohberger1, Susanne Wagner2, Juliana Wohlmuther1, Heike Kaltenegger1, Nicole Stuendl1, Andreas Leithner1, Beate Rinner3, Olaf Kunert4, Rudolf Bauer5, Nadine Kretschmer2.   

Abstract

BACKGROUND: During a screening of Chinese plants traditionally used for the treatment of cancer and related diseases, extracts of the root bark of Periploca sepium Bunge showed strong cytotoxic activity.
PURPOSE: Isolate and identify cytotoxic compounds from P. sepium and investigate the effects and mechanism of action on different cancer cell lines.
METHODS: Extracts obtained with solvents of different polarities of the root bark of P. sepium were tested for their anti-proliferative effects. The most active extract was subjected to activity-guided fractionation using different chromatographic methods. The most active compound was further investigated on sarcoma cell lines regarding its effects concerning apoptosis, DNA damage and death receptor expression.
RESULTS: We isolated the cardiac glycosides periplocin, glucosyl divostroside, periplogenin, periplocymarin and periplocoside M with periplocin exhibiting the lowest IC50 value against leukemia and liposarcoma cells. Liposarcomas are rare tumors within the heterogeneous group of soft tissue sarcomas and respond poorly to conventional treatments. Periplocin led to growth inhibition and apoptosis induction by changing the expression of death receptors and inducing DNA double strand breaks in SW-872 cells.
CONCLUSION: Periplocin displays a promising mechanism of action in sarcoma cells because altering the death receptor expression is an interesting target in sarcoma treatment especially to overcome TRAIL resistance.
Copyright © 2018. Published by Elsevier GmbH.

Entities:  

Keywords:  Apoptosis; Death receptors; Liposarcoma; Periploca sepium; Periplocin

Mesh:

Substances:

Year:  2018        PMID: 30466613     DOI: 10.1016/j.phymed.2018.10.008

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  6 in total

1.  Caspase-Dependent Apoptosis in Prostate Cancer Cells and Zebrafish by Corchorusoside C from Streptocaulon juventas.

Authors:  Gerardo D Anaya-Eugenio; Ermias Mekuria Addo; Nathan Ezzone; Joshua M Henkin; Tran Ngoc Ninh; Yulin Ren; Djaja D Soejarto; A Douglas Kinghorn; Esperanza J Carcache de Blanco
Journal:  J Nat Prod       Date:  2019-05-23       Impact factor: 4.050

2.  Periplocin Induces Apoptosis of Pancreatic Cancer Cells through Autophagy via the AMPK/mTOR Pathway.

Authors:  Hewei Zhang; Yongqiang Wang; Yan Zhang; Beishi Zheng; Xiaowu Wang; Jiawei Chen; Bicheng Chen; Gangyin Xie; Lihong Yang
Journal:  J Oncol       Date:  2022-07-05       Impact factor: 4.501

3.  Periplogenin suppresses the growth of esophageal squamous cell carcinoma in vitro and in vivo by targeting STAT3.

Authors:  Yamei Hu; Fangfang Liu; Xuechao Jia; Penglei Wang; Tingxuan Gu; Hui Liu; Tingting Liu; Huifang Wei; Hanyong Chen; Jiuzhou Zhao; Ran Yang; Yingying Chen; Zigang Dong; Kangdong Liu
Journal:  Oncogene       Date:  2021-05-13       Impact factor: 9.867

4.  Periplocin inhibits the growth of pancreatic cancer by inducing apoptosis via AMPK-mTOR signaling.

Authors:  Gangyin Xie; Linxiao Sun; Yonglin Li; Bicheng Chen; Cheng Wang
Journal:  Cancer Med       Date:  2020-11-24       Impact factor: 4.452

5.  Inhibitory Effects of Periplocin on Lymphoma Cells: A Network Pharmacology Approach and Experimental Validation.

Authors:  Riyang Zhao; Chen Han; Suli Dai; Sisi Wei; Xiaohan Xiang; Yaojie Wang; Ruinian Zhao; Lianmei Zhao; Baoen Shan
Journal:  Drug Des Devel Ther       Date:  2021-03-26       Impact factor: 4.162

6.  Periplocymarin alleviates pathological cardiac hypertrophy via inhibiting the JAK2/STAT3 signalling pathway.

Authors:  Cai-Lian Fan; Sui Liang; Meng-Nan Ye; Wan-Jun Cai; Miao Chen; Yun-Long Hou; Jun Guo; Yi Dai
Journal:  J Cell Mol Med       Date:  2022-04-01       Impact factor: 5.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.